EESO Enzyme Environmental Solutions Inc (CE)

Enzyme Environmental Solutions, Inc. (PINKSHEETS: EESO) CEO Jared Hochstedler recently returned from South Korea with outstanding feedback overall. His visit included both private meetings and live tests with prospective licensees and vendors for various applications of his proprietary industrial/commercial biotechnology. In addition to previously mentioned applications, several other potential solutions were proposed and representatives from other countries took note.

Those in attendance at private meetings and/or live tests in addition to Mr. Hochstedler and Star Towers, as represented by LPMC of Atlanta, Georgia include representatives from Dow Chemicals of Southeast Asia, Han Bool Co., Ltd., a manufacturer of polyethylene, Kolon Industries, who merged with Kolon chemicals in 2007 and M-Cotec company, Ltd.

In addition to corporate contacts, EESO was joined by interested governmental representatives of both Republic of Korea and Japan including representatives from the Department of Ministry of South Korea, Dept. of Disease Control of South Korea, Ministry of Agriculture of Japan and Ministry of Environmental affairs, Japan.

CEO Jared Hochstedler states, "The trip was more than I could have even expected in terms of results and productivity. I expected to come back with promising news regarding feedback, but to come back with negotiations pending and with offers in place is truly exciting. I am pleased to announce that we will be releasing details regarding potential and pending contracts and letters of intent as a result of these meetings in the coming days once we take the time to organize data and feedback and clear it with our new prospective partners."

Safe Harbor: This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact: Newbauer Media Relations Email: mark@enzymeconsultants.com